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nosed and treated for BC with and without metastases. METHODS: Retrospective 
data from 2 large integrated claims databases spanning July 2008 to December 2010 
were used to identify adult patients with a diagnosis of malignant neoplasm of the 
bladder (ICD-9 188.0–188.9; ICD-10 C67.0–67.9). Patients were included if they (1) had 
continuous eligibility for 6 months prior to at least 6 months following their index 
diagnosis, (2) had no diagnosis of any other cancer in the pre-period, and (3) received 
no chemotherapy in the pre-period. Patients were stratified into 2 cohorts based 
on the presence of metastatic disease within 180 days of diagnosis: non-metastatic 
(NM) and metastatic (M). Resource use and all-cause costs (2013 USD) were evalu-
ated after cancer diagnosis. RESULTS: There were 10,250 (9,268 NM, 982 M) and 
22,965 (20,786 NM, 2,179 M) patients in each of the databases meeting all inclusion 
criteria, respectively. Mean follow-up was 35.1 months and 38.6 months in the 2 
datasets. Total costs 6 months prior to index ranged from $6,497–$6,852 (NM) and 
$6,766–$7,831 (M) and increased to $13,127–$13,559 (NM) and $40,695–$45,817 (M) 
in the 6-month post-index period. The majority of costs in the 6-month post-index 
period were attributable to medical services: NM, 88.7%–91.8%; M, 94.8%–96.5%. 
Inpatient and emergency department costs accounted for 38.2%–40.8% (NM) and 
50.4%–52.5% (M) of total medical costs. CONCLUSIONS: Healthcare costs are high-
est among BC patients with metastatic disease, totaling as much as $45,817 in the 
6-month period after diagnosis. Approximately 50% of costs are related to inpatient 
and emergency department services.
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OBJECTIVES: Due to the paucity of data with respect to real-world costs of care 
among individuals with gastric cancer (GaCa), the objective of this analysis is to evalu-
ate the cost of care among individuals diagnosed with GaCa in 2 large retrospective 
databases. METHODS: Two large integrated claims databases spanning July 2008 to 
September 2012 were used to identify patients ≥ 18 years old diagnosed and treated for 
GaCa. Patients were required to be chemotherapy-naïve, continuously enrolled for ≥ 6 
months pre- and post-diagnosis, and have no other cancer diagnosis at baseline. Eligible 
patients were stratified into cohorts based on the presence and timing of metastasis 
(M) diagnosis: no metastasis (NM), ≤ 120 days (M1), and ≥ 121 days (M2). All costs were 
adjusted to 2013 dollars. RESULTS: There were 5,609 (3,486 NM, 1,469 M1, 654 M2) and 
3,203 (2,004 NM, 875 M1, 324 M2) patients in each of the databases, with 189 and 23, 
respectively, without cost data. Mean follow-up was 24 months in one dataset and 25 
months in the other. Total average monthly costs at baseline were: NM $770–$847; M1 
$662–$773; and M2 $634–$1,020. Total average monthly costs during follow-up were: NM 
$1,631–$2,004; M1 $9,813–$9,945; and M2 $6,598–$8,465. Medical costs represented 86%, 
94%, and 93% of monthly costs for NM, M1, and M2 patients, respectively. Overall, 33% of 
patients received chemotherapy during follow-up and mean monthly chemotherapy-
related costs were $966–$1,109, $2,502–$3,079, and $1,480–$1,521 for NM, M1, and M2, 
respectively. CONCLUSIONS: The results demonstrate the high burden to treat this 
population, with the highest costs in the group with metastases at diagnosis (M1) and 
medical-related costs as a major driver of overall treatment costs.
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OBJECTIVES: A substantial proportion of prostate cancer care is expected to be 
completed in the outpatient hospital setting; however, there is limited informa-
tion on the actual cost of care in this setting. The objective of this analysis was 
to evaluate the total annual costs of treatments for castration-resistant prostate 
cancer (CRPC) with bone metastases for the following agents: cabazitaxel, docetaxel, 
radium 223, and sipuleucel-T. METHODS: An economic model was developed from 
the hospital outpatient perspective with a 1-year time horizon. The expected cost 
of each treatment from the outpatient practice perspective was based on reported 
per-visit treatment costs, professional/administration costs, laboratory/monitoring 
costs, and allocated overhead costs. The total treatment cost per visit was mul-
tiplied by the annual number of expected treatment cycles to calculate annual 
treatment costs. Hospital-specific adverse event (AE) costs were applied to pub-
lished grade 3 and 4 AE rates for each comparator and added to the total cost per 
treatment. RESULTS: The total annual cost of therapy was lowest for docetaxel 
($72,051), followed by radium 223 ($92,489), cabazitaxel ($93,742), and sipuleucel-T 
($101,499). The treatment cost per visit was highest for sipuleucel-T ($30,936), fol-
lowed by radium 223 ($12,362), cabazitaxel ($11,564), and docetaxel ($3,396). AE cost 
were $765 for sipuleucel-T, $5,123 for radium 223, $8,074 for cabazitaxel, and $11,223 
for docetaxel. CONCLUSIONS: Total annual costs for CRPC treatments ranged from 
$72,000 to $101,500 per patient. Docetaxel had the lowest total annual costs, followed 
by radium 223, cabazitaxel, then sipuleucel-T, while sipuleucel-T had the lowest AE 
costs followed by radium 223, cabazitaxel, and docetaxel.
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OBJECTIVES: To establish the cost per month of mean overall survival improve-
ment, in Chilean patients treated with ipilimumab, from a third payer perspec-
adoption from the budget holders. However, if discounts approach 30%, physicians 
are likely to have less influence. CONCLUSIONS: Generally, budget holders and 
clinicians have differing views on the utility and placement of biosimilars in the 
clinical pathway. The uptake of which will ultimately depend on geographies, dis-
counts offered and clinician experience. Biosimilars are not going away, however, 
there are strategies that the originator company can utilize and leverage to delay 
uptake and maintain strong market share.
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OBJECTIVES: Post-thoracotomy pain syndrome (PTPS) is widely reported as one 
of the primary comorbidities following lung resection surgery. The objective of 
this retrospective study was to quantify the clinical and economic burden of post-
thoracotomy pain syndrome (PTPS) following lung resection surgery in the United 
States using a large real-world database. METHODS: This study utilized claims data 
from the Truven MarketScan databases. Adult patients undergoing a lobectomy 
or a segmentectomy as the primary surgical procedure were categorized by the 
surgical approach (video-assisted thoracoscopic surgery (VATS) versus open) and 
primary diagnosis (lung cancer vs. non-lung cancer). The PTPS cohort was identified 
based on a diagnosis of non-neurogenic and neurogenic pain lasting more than 
two months post-operatively. Data were collected for: patient demographics, index 
hospital costs and post-discharge costs. Mean, standard deviation, median values 
are reported for observed differences between the groups. RESULTS: A total of 5,502 
patients (4,898 lung cancer and 604 non-lung cancer) met the study criteria. The 
incidence of PTPS was 5% (n= 261) in the cancer group and 7% (n= 42) in the non-
cancer group. PTPS was more common following open procedures vs VATS (6.1% vs. 
4.6%). The one year observed post-discharge costs were consistently higher in the 
PTPS cohort vs. the non-PTPS cohort for both cancer and non-cancer patients with 
a greater difference of mean values in the cancer group (cancer: $36,872±$23,035 
vs. $31,728±$15,176; non-cancer: $16,497±$9,822 vs. $16,040±$5,988). PTPS patients 
diagnosed in the first two months post-operatively cost more to manage than 
the corresponding non-PTPS cohort (cancer: $39,159±$40,030 vs. $32,302±$50,336; 
non-cancer: $16,584±$14,233 vs. $11,005±$19,371). CONCLUSIONS: Real world data 
shows a lower rate of PTPS in the US when compared to data published in the peer-
reviewed literature, suggesting an under-reporting of PTPS in claims databases. 
PTPS is more common following open procedures and the post-discharge cost of 
managing PTPS patients is higher than non-PTPS patients.
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OBJECTIVES: There is increasing clinical evidence to support the adoption of video 
assisted thoracoscopic surgery (VATS) for lung resection procedures. While the 
frequency of significant intraoperative bleeding requiring follow-up interventions 
is generally low, there is a lack of real-world data quantifying its incidence and 
cost of management. The objective of this retrospective study was to quantify the 
clinical and economic burden of significant bleeding in lung resection surgery in 
the United States. METHODS: This study utilized 2009-2012 data from the Premier 
Perspective DatabaseTM. Adult patients with primary pulmonary lobectomy or 
segmentectomy procedures were categorized by the surgical approach (VATS ver-
sus open) and primary diagnosis (lung cancer (primary or metastatic) vs. non-lung 
cancer). Data were collected for patient demographics, length of stay, cost and 
amount of blood product utilized. Patients requiring ≥ 3 units of blood products 
were categorized as the “significant bleeding” cohort. Those requiring < 3 units 
were the “non-significant bleeding” cohort and those not requiring any blood 
products were the “no bleeding” cohort. A matched cohort analysis was performed 
between the “significant bleeding” and the “non-bleeding cohort” using the follow-
ing matching variables: hospital identifier, lung cancer diagnosis, procedure type 
and gender. RESULTS: A total of 29,737 patients (20,370 in the lung cancer group 
and 9,367 in the non-lung cancer group) met the selection criteria. The matched 
cohort analysis showed a higher cost for the “significant bleeding” cohort vs. 
the “non-bleeding” cohort ($32,140 vs. $19,037). The matched analysis for each 
APR-DRG Severity score showed that the significant bleeding cohort cost more 
for the hospital than the non-bleeding cohort. CONCLUSIONS: Significant chest 
bleeding during lung resection surgery is a rare complication in the US, occur-
ring with a frequency of 0.63%. However, patients with significant intraoperative 
bleeding could cost an average of $13,103 more for the hospital to manage and 
have a longer length of stay.
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OBJECTIVES: Recent systematic literature reviews of bladder cancer (BC) indicated 
that more economic research on management strategies, particularly in the meta-
static setting, is needed. This study evaluated the cost of care among patients diag-
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OBJECTIVES: Acute promyelocytic leukemia (APL) is a distinct subtype of acute mye-
loid leukemia (AML) with approximately 1,000 to 1,500 new cases diagnosed each 
year in the United States (US). Trisenox (arsenic trioxide, ATO) is currently licensed 
for the treatment of patients with APL who are refractory to, or have relapsed from 
previous treatment with all-trans retinoic acid (ATRA) and anthracycline-based 
chemotherapy. This analysis evaluated the cost-effectiveness of ATO+ATRA in 
the treatment of newly diagnosed low-to-intermediate risk APL in adult patients, 
compared to two other widely used regimens: ATRA+Ara-C+chemotherapy, and 
ATRA+Idarubicin (AIDA). Cost-effectiveness was measured as incremental cost 
per quality-adjusted life year (QALY) gained and per incremental cost per life year 
(LY) saved from a third-party payer perspective in the US. METHODS: A Markov 
cohort model with monthly cycles and four health states (1st-line stable disease, 
2nd-line stable disease, 2nd-line disease event, and dead) was developed. Patients 
in the model begin treatment at age 45 and were followed until death. Eight 
months duration of ATO+ATRA was compared to either 15 months of ATRA+Ara-
C+chemotherapy or 33 months of AIDA. Efficacy data (event-free survival.overall 
survival) were obtained from key clinical trials. Quality of life/health utility data 
were obtained from the literature. Costs were obtained from standard US data 
sources. Transition probabilities were estimated by calibrating the model to event-
free and overall survival Kaplan-Meier curves for each treatment. Deterministic 
and probabilistic sensitivity analyses were conducted. RESULTS: Compared to 
ATRA+Ara-C+chemotherapy, ATO+ATRA had incremental cost effectiveness ratios 
of $5,900/QALY gained and $4,800/LY saved. ATO+ATRA weakly dominated AIDA 
(had a lower incremental cost-effectiveness ratio and more QALYs and LYs) in newly 
diagnosed patients. The results were robust to sensitivity analysis. CONCLUSIONS: 
The shorter and better-tolerated regimen of ATO+ATRA is a highly cost-effective 
strategy compared to ATRA+Ara-C+chemotherapy or AIDA in the treatment of newly 
diagnosed low-to-intermediate risk APL patients.
PCN74
Cost-effeCtiveNess of radiuM-223 diChloride (radiuM-223) iN 
alsyMPCa: a Cost-effeCtiveNess aNalysis of radiuM-223+Best 
staNdard of Care (BsoC) CoMPared With PlaCeBo+BsoC iN treatMeNt 
of CastratioN-resistaNt Prostate CaNCer (CrPC) aNd syMPtoMatiC 
BoNe Metastases iN CaNada
Henricks P.1, Cislo P.2, Zhan L.2, Beaudet A.3, Grabbi E.4, Lloyd A.4, Fleshner N.5, Chin W.6
1Bayer Inc, Toronto, ON, Canada, 2Bayer HealthCare, Whippany, NJ, USA, 3IMS Health, Basel, 
Switzerland, 4IMS Health, London, UK, 5Princess Margaret Hospital, University Health Network, 
Toronto, ON, Canada, 6ILEX Consulting, Toronto, ON, Canada
OBJECTIVES: In ALSYMPCA, radium-223+BSoC significantly prolonged overall sur-
vival by 3.6 months (HR= 0.70; 95% CI, 0.58-0.83; P< 0.001). Analysis of prospectively 
collected medical resource utilization (MRU) data from ALSYMPCA demonstrated 
that radium-223+BSoC vs BSoC reduced overall MRU, including number of hospi-
talization days/patient/year (8.1 vs 14.6; P< 0.001). An existing cost-effectiveness 
analysis (CEA) model was modified by incorporating the prospective MRU data 
from ALSYMPCA to evaluate their effect on estimated cost-effectiveness of radium-
223+BSoC vs placebo+BSoC in Canada. METHODS: A Markov model was developed 
with 5 health states, reflecting disease progression and SSEs. The Canadian payer 
perspective was used. Quality of life data were from ALSYMPCA; cost inputs were 
from recognized Canadian sources. Costs and outcomes were discounted at a 5% 
annual rate. Model time horizon was 5 years. RESULTS: Incorporating MRU data 
reduced the incremental cost estimate by $11,065 relative to CEA without MRU data 
and improved the incremental cost-effectiveness ratio for radium-223+BSoC vs 
placebo+BSoC by ~35% to $73,408 ($20,098 incremental cost, 0.274 quality-adjusted 
life years [QALYs] gained), substantially lower than the frequently referenced, 
although not explicitly stated, Canadian cancer drug threshold ($100,000/QALY). 
Sensitivity analyses demonstrated robustness of cost-effectiveness results. Patient 
management costs were affected primarily by differential hospital utilization 
between treatment groups. CONCLUSIONS: Including directly observed MRU data 
in this model markedly improved the impact of radium-223 vs modeled benefits 
alone, confirming its cost-effectiveness as a treatment for CRPC with symptomatic 
bone metastases and no visceral metastases. Reduced hospital utilization with 
radium-223 may be driven by delays in time to symptomatic skeletal event (SSE) 
and reduced hospitalization days/patient/year after SSE (Cislo et al. ASCOQCS 2014).
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OBJECTIVES: To evaluate cost-effectiveness of different HPV vaccination as alterna-
tives or additions to the current screening program to prevent and control cervical 
cancer in Mainland China. METHODS: A Markov model was developed for a cohort 
of 100,000 12-year-old girls to simulate the natural history of low risk and high risk 
to HPV infection and its progress to cervical cancer or genital warts. Three recom-
mended screening (protocol 1. Liquid-based cytology test + HPV DNA test; protocol 
2. Pap smear cytology test + HPV DNA test; protocol 3. Visual inspection with acetic 
acid) and two types of HPV vaccination programs (bivalent and quadrivalent vac-
cines) were incorporated to the two kinds of HPV vaccines. Input data were obtained 
from literature review, national databases, and a field study. Sensitivity analyses 
tive. METHODS: We compared ipilimumab treatment for advance melanoma 
with other drugs for advanced cancer that met inclusion criteria including: (1) 
positive phase three study with overall survival as primary or secondary aim, 
(2) authorized by Chilean government agency, and (3) verifiable price in the pri-
vate market. We performed a cost – efficacy analysis, using local prices obtained 
from published local sources to calculate an average cost to progression. Time to 
progression was obtained from published clinical trials. Mean overall survival 
improvement was used as the efficacy metric. Cost – efficacy outputs were plot-
ted and compared. All costs are presented in 2014 USD. Additionally, a survey to 
Chilean oncology specialist was designed to obtain qualitative information about 
their experience(s) with ipilimumab for the treatment of metastatic melanoma 
patients in Chile. RESULTS: Nineteen drugs met inclusion criteria with 28 advance 
cancer indications. The average cost per month of mean survival improvement was 
estimated at $24,802 (range 1,737 – $91,256). We estimated the cost per additional 
month of mean survival improvement at $13,122 and $14.843 for first and second 
line treatment with ipilimumab respectively. Based on the survey, local expert 
opinion unanimously stated that ipilimumab is the best treatment alternative for 
patients with advanced melanoma. CONCLUSIONS: Compared with other inno-
vative drugs for the treatment of advanced cancers, the cost per mean survival 
improvement with ipilimumab was below the average market value and may 
provide good value for money from a third payer perspective in Chile. Based on 
the survey, specialists noted ipilimumab as the best treatment option for Chilean 
patient with advanced melanoma.
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OBJECTIVES: In the ICON7 randomized controlled trial, Oza et al. reported that 
the 502 front line ovarian cancer patients who were at a high-risk of relapse, that 
is patients with stage III suboptimal debulking, stage III unresectable or stage IV 
disease, could benefit most effectively from the addition of bevacizumab (7.5mg/kg) 
to chemotherapy (carboplatin, paclitaxel), compared to chemotherapy alone in the 
front line setting. The objective of this study is to investigate the cost effectiveness 
(CE) of this proposed change in treatment practices. METHODS: Long-term PFS and 
OS were predicted using log-logistic time-to-event parametric functions over a time 
horizon of 10 years. Canadian PFS health state utility values were obtained from the 
mapping of EQ5D scores from ICON7’s high risk patient population. Post progression 
utility values were derived from Naik et al (2014) Canadian study. The cost inputs, 
including standard resource use practices, for this CE model were informed from 
public sources, gynecological oncology experts and ICON7. An annual 5% discount 
rate was applied to both efficacy and costs. A probabilistic sensitivity analysis (PSA) 
as well as one-way sensitivity analyses were conducted. RESULTS: The ICON7 high-
risk patients receiving bevacizumab plus chemotherapy had a mean LY gain of 5.8 
months compared to patients on chemotherapy alone, and a mean QALY gain of 
4.5 months. This resulted in an ICER of $74,084CAD per LY gained and $96,261CAD 
per QALY gained. 55% PSA simulation of the QALY ICERs were at $100,000CAD or 
less. CONCLUSIONS: Although no formal willingness-to-pay threshold exists for 
health technology assessments in Canada, $100,000CAD has been estimated for 
oncology drugs. At a $100,000CAD threshold, bevacizumab in addition to chemo-
therapy provides a cost-effectiveness alternative for high-risk patients (i.e. stage 
III suboptimal debulking, stage III unresectable or stage IV) with ovarian cancer in 
the front line setting.
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OBJECTIVES: This study examined indirect costs in terms of productivity loss 
among patients who received eribulin vs. other commonly used chemotherapies 
in the treatment of metastatic breast cancer (MBC). METHODS: The MarketScan 
Health and Productivity Management Database (2008-2012) was used. Patients 
who initiated eribulin, or received single-agent gemcitabine/capecitabine/vinorel-
bine as the last chemotherapy during the index period (July 2008-Nov 2012) 
were defined as each corresponding study cohort. Adult MBC patients eligible 
for ≥ 1 month employee benefits of short-term disability (STDI) were identified. 
Difference in STDI days was compared between study cohorts using Wilcoxon-
rank-sum-test. STDI-related costs were estimated by multiplying leave days by 
median weekly wages. Two-step generalized linear models were used to estimate 
adjusted indirect costs by controlling for age, payer, region, comorbidities, prior 
chemotherapy, and hormone therapy. RESULTS: A total of 43 patients receiving 
eribulin, 99 gemcitabine, 54 vinorelbine, and 303 capecitabine were eligible for 
STDI (mutually exclusive). Eribulin patients had either similar (vs. gemcitabine 
or vinorelbine) or more (vs. capecitabine) chemotherapy agents prior to initiat-
ing index treatment. Eribulin patients had either numerically lower or similar 
STDI days per-patient-per-month compared to those receiving other therapies 
(6.2±10.8 vs. 8.8±11.0 [gemcitabine], P= .055; 7.1±10.3 [vinorelbine], P= .201; 6.1±9.2 
[capecitabine], P= .295). In addition, eribulin (vs. gemcitabine) patients were less 
likely to have any STDI leave (30% vs. 53%, P= .014). The adjusted mean indirect 
costs associated with STDI per-patient-per-month were $720 (95% CI: $470-$1,102), 
$944 (95% CI: $595-$1,175), $837 (95% CI: $744-$1,198) and $635 (95% CI: $536-
$753) for eribulin, gemcitabine, vinorelbine and capecitabine patients, respec-
tively. CONCLUSIONS: Productivity loss, as measured by utilization of STDI and 
associated costs, tended to be lower in MBC patients treated with eribulin vs. 
gemcitabine and similar to vinorelbine or capecitabine.
